DOJ suit shouldn’t create meaningful overhang for AmerisourceBergen, says BofA

BofA analyst Michael Cherny maintains a Buy rating on AmerisourceBergen after the DOJ filed a civil complaint alleging the company failed to disclose suspicious opioid and other controlled substance orders. The news is "not something that would/should create another meaningful overhang" given that an additional lawsuit on the opioid front "isn’t overly surprising," it is part of an ongoing process and the company, based on its response, is "fighting heavily," Cherny tells investors.